LUNG
Pulmonx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LUNG
Pulmonx Corporation
A global leader in minimally invasive treatments for severe lung disease
Healthcare Equipment and Supplies
--
10/01/2020
NASDAQ Stock Exchange
291
12-31
Common stock
700 Chesapeake Drive, Redwood City, California 94063
--
Pulmonx Corporation was re-incorporated in December 2013 under the laws of the State of Delaware. Pulmonx Corporation is a commercial-grade medical technology company that provides minimally invasive treatment for patients with severe emphysema, a chronic obstructive pulmonary disease. Currently, the company's products are available in 25 countries, and as of December 31, 2019, more than 76,000 valves were used to treat more than 19,000 patients. Among them, the Zephyr valve has been included in the global chronic obstructive pulmonary disease treatment guidelines.
Earnings Call
Q1/2025
Estimate EPS-0.4
Actual EPS-0.36
Estimate Revenue22.03M
Actual Revenue22.50M
Pulmonx's Q1 2025 Earnings Call: Unpacking Contradictions in U.S. Revenue Growth, Tariffs, and Strategic Investments
May 09,2025 03:40
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.4
Actual EPS-0.38
Estimate Revenue23.47M
Actual Revenue23.86M
Pulmonx's Q2 2025 Earnings Call: Unpacking Contradictions in U.S. Revenue Growth and StratX Scanning Trends
Jul 30,2025 10:12
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LUNG has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -0.42, beating expectations. The chart below visualizes how LUNG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LUNG has released its 2025 Q3 earnings report, with revenue of 21.50M, reflecting a YoY change of 5.47%, and net profit of -13.96M, showing a YoY change of 1.32%. The Sankey diagram below clearly presents LUNG's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
